Simvastatin enhances bone formation around titanium implants in rat tibiae.
Statins are cholesterol-lowering drugs that have been reported to promote bone formation. The purpose of this study was to investigate the effect of simvastatin on the enhancement of bone formation around titanium implants. Thirty-week-old female rats received pure titanium implants in both tibiae. The animals were intra-peritoneally administered 0, 0.125, 1, 5 or 10 mg kg(-1) of simvastatin daily. After 30 days, the animals were sacrificed, and specimens were prepared. The bone contact ratio of the implant, bone density in the medullary canal and percentage of cortical bone were obtained. Markers for bone turnover were also measured using sera collected at the time of euthanasia. In the medullary canal, a scanty amount of bone was observed in the 0, 0.125 and 1 mg kg(-1) groups. In contrast, in both the 5 and 10 mg kg(-1) groups, thicker bone trabeculae were abundant. Histometric observations showed that the bone contact ratio and the bone density of both groups were significantly greater than those of the other groups (anova, P < 0.01). However, no significant difference in the percentage of cortical bone was found between groups. Serum chemistry showed that statin increased bone formation markers and decreased bone resorption markers. In conclusion, although the dose equivalent to that used in human patients with hypercholesterolemia was not effective, a simvastatin dose of 5 mg kg(-1) or higher increased medullary bone formation around the titanium. In contrast, no effect of simvastatin on pre-existing cortical bone was indicated.
Ayukawa
Y
Y
Section of Removable Prosthodontics, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Maidashi, Higashi-ku, Fukuoka, Japan. ayukawa@dent.kyushu-u.ac.jp
Ogino
Y
Y
Moriyama
Y
Y
Atsuta
I
I
Jinno
Y
Y
Kihara
M
M
Tsukiyama
Y
Y
Koyano
K
K
D000135:Acid Phosphatase / Q000097:blood; D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001862:Bone Resorption / Q000097:blood; D003124:Colorimetry; D015921:Dental Implants; D003764:Dental Materials / Q000737:chemistry; D005260:Female; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D007527:Isoenzymes / Q000097:blood; D016348:Osseointegration / Q000502:physiology; D015675:Osteocalcin / Q000097:blood; D010012:Osteogenesis / Q000187:drug effects*; D051381:Rats; D019821:Simvastatin / Q000008:administration & dosage / Q000494:pharmacology*; D000071681:Tartrate-Resistant Acid Phosphatase; D013977:Tibia / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D014025:Titanium / Q000737:chemistry
D000924:Anticholesteremic Agents; D015415:Biomarkers; D015921:Dental Implants; D003764:Dental Materials; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007527:Isoenzymes; D015675:Osteocalcin; D019821:Simvastatin; D014025:Titanium; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase